The FGL1/LAG-3 interaction could potentially contribute to the resistance of anti-PD therapy in human cancers, and thus, FGL1 overexpression in the plasma of cancer patients is associated with poor prognosis and resistance to anti-PD-1/PD-L1 therapy. This evidence concerns the gene FGL1 and cancer.